Search

Your search keyword '"Ahnen, Dennis J."' showing total 737 results
Start Over Author "Ahnen, Dennis J."

Refine your results

more »

more »

more »

more »

more »
737 results on '"Ahnen, Dennis J."'

1. Potential impact of family history–based screening guidelines on the detection of early‐onset colorectal cancer

Author

Gupta, Samir, Bharti, Balambal, Ahnen, Dennis J, Buchanan, Daniel D, Cheng, Iona C, Cotterchio, Michelle, Figueiredo, Jane C, Gallinger, Steven J, Haile, Robert W, Jenkins, Mark A, Lindor, Noralane M, Macrae, Finlay A, Le Marchand, Loïc, Newcomb, Polly A, Thibodeau, Stephen N, Win, Aung Ko, and Martinez, Maria Elena

Subjects
Prevention, Cancer, Health Services, Digestive Diseases, Aging, Clinical Research, Colo-Rectal Cancer, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, 4.4 Population screening, Adult, Age Factors, Age of Onset, Case-Control Studies, Colorectal Neoplasms, Early Detection of Cancer, Family Health, Female, Humans, Male, Middle Aged, Practice Guidelines as Topic, Retrospective Studies, Sensitivity and Specificity, case-control study, family history, guidelines, sensitivity, specificity, young-onset colorectal cancer, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundInitiating screening at an earlier age based on cancer family history is one of the primary recommended strategies for the prevention and detection of early-onset colorectal cancer (EOCRC), but data supporting the effectiveness of this approach are limited. The authors assessed the performance of family history-based guidelines for identifying individuals with EOCRC.MethodsThe authors conducted a population-based, case-control study of individuals aged 40 to 49 years with (2473 individuals) and without (772 individuals) incident CRC in the Colon Cancer Family Registry from 1998 through 2007. They estimated the sensitivity and specificity of family history-based criteria jointly recommended by the American Cancer Society, the US Multi-Society Task Force on CRC, and the American College of Radiology in 2008 for early screening, and the age at which each participant could have been recommended screening initiation if these criteria had been applied.ResultsFamily history-based early screening criteria were met by approximately 25% of cases (614 of 2473 cases) and 10% of controls (74 of 772 controls), with a sensitivity of 25% and a specificity of 90% for identifying EOCRC cases aged 40 to 49 years. Among 614 individuals meeting early screening criteria, 98.4% could have been recommended screening initiation at an age younger than the observed age of diagnosis.ConclusionsOf CRC cases aged 40 to 49 years, 1 in 4 met family history-based early screening criteria, and nearly all cases who met these criteria could have had CRC diagnosed earlier (or possibly even prevented) if earlier screening had been implemented as per family history-based guidelines. Additional strategies are needed to improve the detection and prevention of EOCRC for individuals not meeting family history criteria for early screening.

Published
2020

2. Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes

Author

Thompson, Patricia A, Ashbeck, Erin L, Roe, Denise J, Fales, Liane, Buckmeier, Julie, Wang, Fang, Bhattacharyya, Achyut, Hsu, Chiu-Hsieh, Chow, HH Sherry, Ahnen, Dennis J, Boland, C Richard, Heigh, Russell I, Fay, David E, Hamilton, Stanley R, Jacobs, Elizabeth T, Martinez, Maria Elena, Alberts, David S, and Lance, Peter

Subjects
Clinical Research, Prevention, Nutrition, Aging, Diabetes, Clinical Trials and Supportive Activities, Digestive Diseases, Colo-Rectal Cancer, Cancer, Complementary and Integrative Health, 3.3 Nutrition and chemoprevention, Prevention of disease and conditions, and promotion of well-being, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adenoma, Aged, Colorectal Neoplasms, Cyclooxygenase 2 Inhibitors, Diabetes Mellitus, Type 2, Dietary Supplements, Female, Follow-Up Studies, Humans, Male, Medication Adherence, Middle Aged, Neoplasms, Second Primary, Risk Assessment, Selenium, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Selenium supplementation may help to prevent colorectal cancer; as precursors of colorectal cancer, colorectal adenomas are a surrogate for colorectal cancer. Selenium supplementation may increase risk of type 2 diabetes (T2D). The Selenium and Celecoxib (Sel/Cel) Trial was a randomized, placebo controlled trial of selenium 200 µg daily as selenized yeast and celecoxib 400 mg once daily, alone or together, for colorectal adenoma prevention. Men and women between age 40 and 80 years were eligible following colonoscopic removal of colorectal adenomas. The primary outcome was adenoma development. Celecoxib was suspended because of cardiovascular toxicity in other trials, but accrual continued to selenium and placebo. A total of 1621 participants were randomly assigned to selenium or placebo, of whom 1374 (84.8%) were available for analysis. All statistical tests were two-sided. In the respective placebo and selenium arms of 689 and 685 participants, adenoma detection after medians of 33.6 (range = 0.0-85.1 months) and 33.0 months (range = 0.0-82.6 months) were 42.8% and 44.1% (relative risk [RR] = 1.03, 95% confidence interval [CI] = 0.91 to 1.16, P = .68). In participants with baseline advanced adenomas, adenoma recurrence was reduced by 18% with selenium (RR = 0.82, 95% CI = 0.71 to 0.96, P = .01). In participants receiving selenium, the hazard ratio for new-onset T2D was 1.25 (95% CI = 0.74 to 2.11, P = .41), with a statistically significantly increased risk of selenium-associated T2D among older participants (RR = 2.21; 95% CI = 1.04 to 4.67, P = .03). Overall, selenium did not prevent colorectal adenomas and showed only modest benefit in patients with baseline advanced adenomas. With limited benefit and similar increases in T2D to other trials, selenium is not recommended for preventing colorectal adenomas in selenium-replete individuals.

Published
2016

4. Prevalence of Advanced Colorectal Neoplasia in Veterans: Effects of Age, Sex, and Race/Ethnicity

Author

Imperiale, Thomas F., Daggy, Joanne K., Imler, Timothy D., Sherer, Eric A., Kahi, Charles J., Larson, Jason, Cardwell, Jon, Johnson, Cynthia S., Ahnen, Dennis J., Antaki, Fadi, Ashley, Christopher, Baffy, Gyorgy, Dominitz, Jason A., Hou, Jason, Korsten, Mark A., Nagar, Anil, Promrat, Kittichai, Robertson, Douglas J., Saini, Sameer, Shergill, Amandeep, and Smalley, Walter E.

Published
2021
Full Text
View/download PDF

5. Ability of known susceptibility SNPs to predict colorectal cancer risk for persons with and without a family history

Author

Jenkins, Mark A., Win, Aung K., Dowty, James G., MacInnis, Robert J., Makalic, Enes, Schmidt, Daniel F., Dite, Gillian S., Kapuscinski, Mirosl, Clendenning, Mark, Rosty, Christophe, Winship, Ingrid M., Emery, Jon D., Saya, Sibel, Macrae, Finlay A., Ahnen, Dennis J., Duggan, David, Figueiredo, Jane C., Lindor, Noralane M., Haile, Robert W., Potter, John D., Cotterchio, Michelle, Gallinger, Steven, Newcomb, Polly A., Buchanan, Daniel D., Casey, Graham, and Hopper, John L.

Published
2019
Full Text
View/download PDF

6. Activating mutation in MET oncogene in familial colorectal cancer

Author

Neklason, Deborah W, Done, Michelle W, Sargent, Nykole R, Schwartz, Ann G, Anton-Culver, Hoda, Griffin, Constance A, Ahnen, Dennis J, Schildkraut, Joellen M, Tomlinson, Gail E, Strong, Louise C, Miller, Alexander R, Stopfer, Jill E, and Burt, Randall W

Abstract

Abstract Background In developed countries, the lifetime risk of developing colorectal cancer (CRC) is 5%, and it is the second leading cause of death from cancer. The presence of family history is a well established risk factor with 25-35% of CRCs attributable to inherited and/or familial factors. The highly penetrant inherited colon cancer syndromes account for approximately 5%, leaving greater than 20% without clear genetic definition. Familial colorectal cancer has been linked to chromosome 7q31 by multiple affected relative pair studies. The MET proto-oncogene which resides in this chromosomal region is considered a candidate for genetic susceptibility. Methods MET exons were amplified by PCR from germline DNA of 148 affected sibling pairs with colorectal cancer. Amplicons with altered sequence were detected with high-resolution melt-curve analysis using a LightScanner (Idaho Technologies). Samples demonstrating alternative melt curves were sequenced. A TaqMan assay for the specific c.2975C > T change was used to confirm this mutation in a cohort of 299 colorectal cancer cases and to look for allelic amplification in tumors. Results Here we report a germline non-synonymous change in the MET proto-oncogene at amino acid position T992I (also reported as MET p.T1010I) in 5.2% of a cohort of sibling pairs affected with CRC. This genetic variant was then confirmed in a second cohort of individuals diagnosed with CRC and having a first degree relative with CRC at prevalence of 4.1%. This mutation has been reported in cancer cells of multiple origins, including 2.5% of colon cancers, and in

Published
2011

7. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.

Author

Meyskens, Frank L, Jr, McLaren, Christine E, Pelot, Daniel, Fujikawa-Brooks, Sharon, Carpenter, Philip M, Hawk, Ernest, Kelloff, Gary, Lawson, Michael J, Kidao, Jayashri, McCracken, John, Albers, C Gregory, Ahnen, Dennis J, Turgeon, D Kim, Goldschmid, Steven, Lance, Peter, Hagedorn, Curt H, Gillen, Daniel L, and Gerner, Eugene W

Subjects
Adenoma: diagnosis, prevention & control, Adult, Aged, Algorithms, Antineoplastic Combined Chemotherapy Protocols: adverse effects, therapeutic use, Colonoscopy, Colorectal Neoplasms: diagnosis, prevention & control, Double-Blind Method, Eflornithine: administration & dosage, adverse effects, Female, Humans, Male, Middle Aged, Placebos, Sulindac: administration & dosage, adverse effects, Treatment Outcome, antineoplastic agent, eflornithine, placebo, sulindac, adenoma, adult, aged, algorithm, article, clinical trial, colonoscopy, colorectal tumor, controlled clinical trial, controlled study, double blind procedure, female, human, male, middle aged, randomized controlled trial, treatment outcome, Adenoma, Adult, Aged, Algorithms, Antineoplastic Combined Chemotherapy Protocols, Colonoscopy, Colorectal Neoplasms, Double-Blind Method, Eflornithine, Female, Humans, Male, Middle Aged, Placebos, Sulindac, Treatment Outcome
Abstract

Preclinical studies of chemoprevention drugs given in combination at low doses show remarkable efficacy in preventing adenomas with little additional toxicities, suggesting a strategy to improve risk to benefit ratios for preventing recurrent adenomas. Three hundred seventy-five patients with history of resected (> or =3 mm) adenomas were randomly assigned to receive oral difluoromethylornithine (DFMO) 500 mg and sulindac 150 mg once daily or matched placebos for 36 months, stratified by use of low-dose aspirin (81 mg) at baseline and clinical site. Follow-up colonoscopy was done 3 years after randomization or off-study. Colorectal adenoma recurrence was compared among the groups with log-binomial regression. Comparing the outcome in patients receiving placebos to those receiving active intervention, (a) the recurrence of one or more adenomas was 41.1% and 12.3% (risk ratio, 0.30; 95% confidence interval, 0.18-0.49; P < 0.001); (b) 8.5% had one or more advanced adenomas, compared with 0.7% of patients (risk ratio, 0.085; 95% confidence interval, 0.011-0.65; P < 0.001); and (c) 17 (13.2%) patients had multiple adenomas (>1) at the final colonoscopy, compared with 1 (0.7%; risk ratio, 0.055; 0.0074-0.41; P < 0.001). Serious adverse events (grade > or =3) occurred in 8.2% of patients in the placebo group, compared with 11% in the active intervention group (P = 0.35). There was no significant difference in the proportion of patients reporting hearing changes from baseline. Recurrent adenomatous polyps can be markedly reduced by a combination of low oral doses of DFMO and sulindac and with few side effects.

Published
2008

16. Supplementary Data from No Evidence for Posttreatment Effects of Vitamin D and Calcium Supplementation on Risk of Colorectal Adenomas in a Randomized Trial

Author

Calderwood, Audrey H., primary, Baron, John A., primary, Mott, Leila A., primary, Ahnen, Dennis J., primary, Bostick, Roberd M., primary, Figueiredo, Jane C., primary, Passarelli, Michael N., primary, Rees, Judy R., primary, Robertson, Douglas J., primary, and Barry, Elizabeth L., primary

Published
2023
Full Text
View/download PDF

21. Data from Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial

Author

Meyskens, Frank L., primary, McLaren, Christine E., primary, Pelot, Daniel, primary, Fujikawa-Brooks, Sharon, primary, Carpenter, Philip M., primary, Hawk, Ernest, primary, Kelloff, Gary, primary, Lawson, Michael J., primary, Kidao, Jayashri, primary, McCracken, John, primary, Albers, C. Gregory, primary, Ahnen, Dennis J., primary, Turgeon, D. Kim, primary, Goldschmid, Steven, primary, Lance, Peter, primary, Hagedorn, Curt H., primary, Gillen, Daniel L., primary, and Gerner, Eugene W., primary

Published
2023
Full Text
View/download PDF

22. Perspective from Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial

Author

Meyskens, Frank L., primary, McLaren, Christine E., primary, Pelot, Daniel, primary, Fujikawa-Brooks, Sharon, primary, Carpenter, Philip M., primary, Hawk, Ernest, primary, Kelloff, Gary, primary, Lawson, Michael J., primary, Kidao, Jayashri, primary, McCracken, John, primary, Albers, C. Gregory, primary, Ahnen, Dennis J., primary, Turgeon, D. Kim, primary, Goldschmid, Steven, primary, Lance, Peter, primary, Hagedorn, Curt H., primary, Gillen, Daniel L., primary, and Gerner, Eugene W., primary

Published
2023
Full Text
View/download PDF

24. Data from Shifts in the Fecal Microbiota Associated with Adenomatous Polyps

Author

Hale, Vanessa L., primary, Chen, Jun, primary, Johnson, Stephen, primary, Harrington, Sean C., primary, Yab, Tracy C., primary, Smyrk, Thomas C., primary, Nelson, Heidi, primary, Boardman, Lisa A., primary, Druliner, Brooke R., primary, Levin, Theodore R., primary, Rex, Douglas K., primary, Ahnen, Dennis J., primary, Lance, Peter, primary, Ahlquist, David A., primary, and Chia, Nicholas, primary

Published
2023
Full Text
View/download PDF

25. Supplemental Table 1 from Association of the Colorectal CpG Island Methylator Phenotype with Molecular Features, Risk Factors, and Family History

Author

Weisenberger, Daniel J., primary, Levine, A. Joan, primary, Long, Tiffany I., primary, Buchanan, Daniel D., primary, Walters, Rhiannon, primary, Clendenning, Mark, primary, Rosty, Christophe, primary, Joshi, Amit D., primary, Stern, Mariana C., primary, Le Marchand, Loic, primary, Lindor, Noralane M., primary, Daftary, Darshana, primary, Gallinger, Steven, primary, Selander, Teresa, primary, Bapat, Bharati, primary, Newcomb, Polly A., primary, Campbell, Peter T., primary, Casey, Graham, primary, Ahnen, Dennis J., primary, Baron, John A., primary, Haile, Robert W., primary, Hopper, John L., primary, Young, Joanne P., primary, Laird, Peter W., primary, and Siegmund, Kimberly D., primary

Published
2023
Full Text
View/download PDF

26. Table S1 from Shifts in the Fecal Microbiota Associated with Adenomatous Polyps

Author

Hale, Vanessa L., primary, Chen, Jun, primary, Johnson, Stephen, primary, Harrington, Sean C., primary, Yab, Tracy C., primary, Smyrk, Thomas C., primary, Nelson, Heidi, primary, Boardman, Lisa A., primary, Druliner, Brooke R., primary, Levin, Theodore R., primary, Rex, Douglas K., primary, Ahnen, Dennis J., primary, Lance, Peter, primary, Ahlquist, David A., primary, and Chia, Nicholas, primary

Published
2023
Full Text
View/download PDF

27. Suppementary Figure 1 from Shifts in the Fecal Microbiota Associated with Adenomatous Polyps

Author

Hale, Vanessa L., primary, Chen, Jun, primary, Johnson, Stephen, primary, Harrington, Sean C., primary, Yab, Tracy C., primary, Smyrk, Thomas C., primary, Nelson, Heidi, primary, Boardman, Lisa A., primary, Druliner, Brooke R., primary, Levin, Theodore R., primary, Rex, Douglas K., primary, Ahnen, Dennis J., primary, Lance, Peter, primary, Ahlquist, David A., primary, and Chia, Nicholas, primary

Published
2023
Full Text
View/download PDF

28. Data from A Randomized Trial to Increase Colonoscopy Screening in Members of High-Risk Families in the Colorectal Cancer Family Registry and Cancer Genetics Network

Author

Lowery, Jan T., primary, Horick, Nora, primary, Kinney, Anita Y., primary, Finkelstein, Dianne M., primary, Garrett, Kathleen, primary, Haile, Robert W., primary, Lindor, Noralane M., primary, Newcomb, Polly A., primary, Sandler, Robert S., primary, Burke, Carol, primary, Hill, Deirdre A., primary, and Ahnen, Dennis J., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 2 from BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics

Author

Phipps, Amanda I., primary, Buchanan, Daniel D., primary, Makar, Karen W., primary, Burnett-Hartman, Andrea N., primary, Coghill, Anna E., primary, Passarelli, Michael N., primary, Baron, John A., primary, Ahnen, Dennis J., primary, Win, Aung Ko, primary, Potter, John D., primary, and Newcomb, Polly A., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 1 from BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics

Author

Phipps, Amanda I., primary, Buchanan, Daniel D., primary, Makar, Karen W., primary, Burnett-Hartman, Andrea N., primary, Coghill, Anna E., primary, Passarelli, Michael N., primary, Baron, John A., primary, Ahnen, Dennis J., primary, Win, Aung Ko, primary, Potter, John D., primary, and Newcomb, Polly A., primary

Published
2023
Full Text
View/download PDF

31. Data from Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer

Author

Win, Aung Ko, primary, Jenkins, Mark A., primary, Dowty, James G., primary, Antoniou, Antonis C., primary, Lee, Andrew, primary, Giles, Graham G., primary, Buchanan, Daniel D., primary, Clendenning, Mark, primary, Rosty, Christophe, primary, Ahnen, Dennis J., primary, Thibodeau, Stephen N., primary, Casey, Graham, primary, Gallinger, Steven, primary, Le Marchand, Loïc, primary, Haile, Robert W., primary, Potter, John D., primary, Zheng, Yingye, primary, Lindor, Noralane M., primary, Newcomb, Polly A., primary, Hopper, John L., primary, and MacInnis, Robert J., primary

Published
2023
Full Text
View/download PDF

32. FHPP Baseline Survey from A Randomized Trial to Increase Colonoscopy Screening in Members of High-Risk Families in the Colorectal Cancer Family Registry and Cancer Genetics Network

Author

Lowery, Jan T., primary, Horick, Nora, primary, Kinney, Anita Y., primary, Finkelstein, Dianne M., primary, Garrett, Kathleen, primary, Haile, Robert W., primary, Lindor, Noralane M., primary, Newcomb, Polly A., primary, Sandler, Robert S., primary, Burke, Carol, primary, Hill, Deirdre A., primary, and Ahnen, Dennis J., primary

Published
2023
Full Text
View/download PDF

33. Appendix - clean version from Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer

Author

Win, Aung Ko, primary, Jenkins, Mark A., primary, Dowty, James G., primary, Antoniou, Antonis C., primary, Lee, Andrew, primary, Giles, Graham G., primary, Buchanan, Daniel D., primary, Clendenning, Mark, primary, Rosty, Christophe, primary, Ahnen, Dennis J., primary, Thibodeau, Stephen N., primary, Casey, Graham, primary, Gallinger, Steven, primary, Le Marchand, Loïc, primary, Haile, Robert W., primary, Potter, John D., primary, Zheng, Yingye, primary, Lindor, Noralane M., primary, Newcomb, Polly A., primary, Hopper, John L., primary, and MacInnis, Robert J., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Tables from Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer

Author

Win, Aung Ko, primary, Jenkins, Mark A., primary, Dowty, James G., primary, Antoniou, Antonis C., primary, Lee, Andrew, primary, Giles, Graham G., primary, Buchanan, Daniel D., primary, Clendenning, Mark, primary, Rosty, Christophe, primary, Ahnen, Dennis J., primary, Thibodeau, Stephen N., primary, Casey, Graham, primary, Gallinger, Steven, primary, Le Marchand, Loïc, primary, Haile, Robert W., primary, Potter, John D., primary, Zheng, Yingye, primary, Lindor, Noralane M., primary, Newcomb, Polly A., primary, Hopper, John L., primary, and MacInnis, Robert J., primary

Published
2023
Full Text
View/download PDF

35. Figure S3 from Shifts in the Fecal Microbiota Associated with Adenomatous Polyps

Author

Hale, Vanessa L., primary, Chen, Jun, primary, Johnson, Stephen, primary, Harrington, Sean C., primary, Yab, Tracy C., primary, Smyrk, Thomas C., primary, Nelson, Heidi, primary, Boardman, Lisa A., primary, Druliner, Brooke R., primary, Levin, Theodore R., primary, Rex, Douglas K., primary, Ahnen, Dennis J., primary, Lance, Peter, primary, Ahlquist, David A., primary, and Chia, Nicholas, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results